Mylan launches its generic schizophrenia drug

Mylan has launched of Perphenazine Tablets USP, a generic version of Schering‘s Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg.

U.S. Food and Drug Administration (FDA) gave Mylan final approval for Abbreviated New Drug Application (ANDA) for this product, which is used in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

The company said, refering to IMS Health, that Perphenazine Tablets USP had U.S. sales of approximately $41 million for the 12 months ending Feb. 28, 2017.

Mylan said that it has 236 ANDAs pending FDA approval representing approximately $104.3 billion in annual brand sales. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $42.7 billion in annual brand sales, for the 12 months ending Dec. 31, 2016, according to IMS Health.